IOVANCE CCO awarded 132,200 RSUs

Kirby Daniel Gordon reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Kirby Daniel Gordon reported acquisition or exercise transactions in this Form 4 filing.

IOVANCE BIOTHERAPEUTICS, INC. Chief Commercial Officer Daniel Kirby received a grant of 132,200 restricted stock units. Each RSU represents a contingent right to receive one share of common stock. After this grant, he holds 132,200 RSUs.

The RSUs vest over three years if he remains employed. One-third vests on the one-year anniversary of the grant date, and the remaining units vest in eight equal quarterly installments over the following two years.

Insider Trade Summary

Grant/Award: 132,200 shares

Grant/Award 1 txn

Insider Kirby Daniel Gordon

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	132,200	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 132,200 contracts (Direct)

Footnotes (2)

1. F1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
2. F2. Provided the Reporting Person is still employed with the Issuer on the following dates, the RSUs shall vest over three years, with (i) one-third of the RSUs vesting on the one-year anniversary of the date of grant and (ii) the remaining RSUs shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did IOVANCE BIOTHERAPEUTICS (IOVA) report for Daniel Kirby?

IOVANCE BIOTHERAPEUTICS reported that Chief Commercial Officer Daniel Kirby received 132,200 restricted stock units as a grant. These RSUs are a form of equity compensation rather than an open-market stock purchase or sale, aligning his interests with longer-term company performance.

How many restricted stock units did the IOVA Chief Commercial Officer receive?

The Chief Commercial Officer of IOVANCE BIOTHERAPEUTICS received 132,200 restricted stock units. Each RSU represents a contingent right to one share of common stock, providing potential future ownership if vesting conditions and continued employment requirements are satisfied over the three-year schedule.

What is the vesting schedule for Daniel Kirby’s IOVA restricted stock units?

The 132,200 RSUs vest over three years, conditional on continued employment. One-third vests on the first anniversary of the grant date. The remaining RSUs then vest in eight equal quarterly installments across the following two years, gradually delivering share rights over time.

Does the IOVA Form 4 show a stock sale or purchase by Daniel Kirby?

The Form 4 shows a grant of 132,200 restricted stock units to Daniel Kirby, not an open-market stock sale or purchase. It is categorized as a grant or award acquisition, reflecting equity-based compensation rather than a discretionary trading decision in the market.

How many IOVANCE BIOTHERAPEUTICS RSUs does Daniel Kirby hold after this grant?

Following this transaction, Daniel Kirby holds 132,200 restricted stock units. This figure reflects his position after receiving the new grant, providing potential future common shares if the time-based vesting and continued employment conditions outlined in the award are met.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/11/2026 - 05:01 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kirby Daniel Gordon

(Last) (First) (Middle)

C/O IOVANCE BIOTHERAPEUTICS, INC.

825 INDUSTRIAL ROAD, SUITE 100

(Street)

SAN CARLOS CA 94070

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IOVANCE BIOTHERAPEUTICS, INC. [ IOVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	03/09/2026		A		132,200		(2)	(2)	Common Stock	132,200	$0.00	132,200	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

2. Provided the Reporting Person is still employed with the Issuer on the following dates, the RSUs shall vest over three years, with (i) one-third of the RSUs vesting on the one-year anniversary of the date of grant and (ii) the remaining RSUs shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant.

	/s/ Daniel Gordon Kirby	03/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.